London

Roots Analysis has announced the addition of “Polycystic Ovary Syndrome Market, 2021-2031” report to its list of offerings.

Currently, there is no cure for polycystic ovary syndrome (PCOS / PCOD), however the affiliated symptoms can be treated using a combination of different types of medications, including insulin-sensitizing agents, oral contraceptives, anti-androgens and anti-obesity drugs. The research activities, including clinical investigations in this domain are being driven by both industry and non-industry players.

To order this 90+ page report, which features 70+ figures, please visit https://www.rootsanalysis.com/reports/polycystic-ovarian-syndrome-m...

Key Market Insights

Currently, more than 60 drugs are marketed / under development for PCOS
More than 80% of the drugs in the market are designed for symptomatic treatment of PCOS whilst a few drugs are being evaluated for curing this clinical condition. Among various types of drugs available, hormonal contraceptives and insulin sensitizing agents are used for the first line treatment. Popular hormonal contraceptives include Beyaz®, Clomid®, Diane 35® and Yasmin®.

More than 40 industry and non-industry players are engaged in the development of drugs for PCOS
Majority of the industry players (70%) are very large firms (having more than 500 employees). North America is the current hub, where close to 45% players are based. This is followed by Europe (28%), Asia-Pacific (9%), and Middle East and North Africa (7%).

Close to 3,800 patents have been filed / granted related to PCOS, since 2016
Around 60% of these are patent applications, while rest of the patents have been granted. Further, R&D activity related to PCOS is largely concentrated in the US, where over 50% of the total number of patents were filed. Leading industry players (in terms of the size of intellectual property portfolio) include Bristol Myers Squibb, Genentech, Merck and Zafgen.

The market is anticipated to grow at a CAGR of 4%, during the period 2021-2031
Growth in this domain is anticipated to be driven by the sales of insulin-sensitizing agents that are expected to capture over 45% of the market share by 2031. Further, majority share (83%) of the market is captured by oral drugs

To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/polycystic-ovarian-syndrome-m...

For additional details, please visit
https://www.rootsanalysis.com/reports/polycystic-ovarian-syndrome-m... or email [email protected]

You may also be interested in the following titles:
1. Non-hormonal Therapies for Women’s Health Market, 2021-2030
2. Squamous Non-Small Cell Lung Cancer: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031
3. Vascular Disrupting Agents Market, 2021-2030

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Details
Ben Johnson
+1 (415) 800 3415
[email protected]

Roots Analysis
Web: https://medium.com/@RootsAnalysis
LinkedIn: https://medium.com/@RootsAnalysis
Twitter: https://medium.com/@RootsAnalysis
Medium: https://medium.com/@RootsAnalysis
Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/
Quora: https://rootsanalysisinsights.quora.com/